✦ LIBER ✦

Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: An open-label single-arm study

✍ Scribed by Chang, Gee-Chen; Tsai, Chun-Ming; Hsia, Te-Chun; Yang, Chih-Hsin; Abdulnabi, Radhi; Blair, Julie M.; Linn, Carlos

Book ID: 122079975
Publisher: Chinese Electronic Periodical Services
Year: 2013
Tongue: English
Weight: 656 KB
Volume: 112
Category: Article
ISSN: 0929-6646
DOI: 10.1016/j.jfma.2012.02.030

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Second-line pemetrexed versus docetaxel

Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study

✍ Sun, Y.; Wu, Y.-L.; Zhou, C.-C.; Zhang, L.; Zhang, L.; Liu, X.-Y.; Yu, S.-Y.; Ji 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 326 KB

Gefitinib versus pemetrexed as second-li

Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01) : An open-label, phase 3 trial

✍ Jong-Mu Sun; Ki Hyeong Lee; Sang-we Kim; Dae Ho Lee; Young Joo Min; Hwan Jung Yu 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB

Phase II study of pemetrexed in combinat

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer

✍ Ralph G. Zinner; Frank V. Fossella; Gregory W. Gladish; Bonnie S. Glisson; Georg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 3 views

An open-label study of vandetanib with p

An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer

✍ de Boer, R.; Humblet, Y.; Wolf, J.; Nogova, L.; Ruffert, K.; Milenkova, T.; Smit 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 136 KB

A single-arm, multicenter, open-label ph

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma

✍ Christian Wülfing; Jean-Pascal H. Machiels; Dirk J. Richel; Marc-Oliver Grimm; U 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 1 views

Pemetrexed versus gefitinib as a second-

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial

✍ Zhou, Q.; Cheng, Y.; Yang, J.- J.; Zhao, M.- F.; Zhang, L.; Zhang, X.- C.; Chen, 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 228 KB